前列腺癌的管理在所有疾病情况下都在快速变化。新的诊断影像工具已经被引入，近年来，高风险局部限定、局部晚期和转移性疾病的治疗方式发生了很大变化。从临床和卫生经济学角度来看，合理和最佳利用现有选择的重要性不言而喻。虽然国际指南列出了相关关键试验并对各种临床情况提出了建议，但解释空间很大，还有几个重要问题仍然存在激烈争议。制定关于这些新的诊断和治疗策略使用的国家共识，以改善疾病管理并最终提高患者的预后，这是瑞士共识会议的目标。来自多个专业领域的专家，包括泌尿外科、医学肿瘤学、放射肿瘤学、病理学和核医学，讨论并投票对当前最重要的不确定领域的问题，包括高风险局部限定疾病的分期和治疗，治疗转移性激素敏感前列腺癌（mHSPC）以及使用新疗法治疗转移性去势抵抗性前列腺癌（mCRPC）。

The management of prostate cancer is undergoing rapid changes in all disease settings. Novel imaging tools for diagnosis have been introduced, and the treatment of high-risk localized, locally advanced and metastatic disease has changed considerably in recent years. From clinical and health-economic perspectives, a rational and optimal use of the available options is of the utmost importance. While international guidelines list relevant pivotal trials and give recommendations for a variety of clinical scenarios, there is much room for interpretation, and several important questions remain highly debated. The goal of developing a national consensus on the use of these novel diagnostic and therapeutic strategies in order to improve disease management and eventually patient outcomes has prompted a Swiss consensus meeting. Experts from several specialties, including urology, medical oncology, radiation oncology, pathology and nuclear medicine, discussed and voted on questions of the current most important areas of uncertainty, including the staging and treatment of high-risk localized disease, treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and use of new options to treat metastatic castration-resistant prostate cancer (mCRPC).